Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies

Journal of Clinical Pharmacology

Volumn 55, Issue S3, 2015, Pages S51-S59

  Mould, Diane R ^a   Dubinsky, Marla C ^b  

^a Projections Research Inc   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

inflammatory bowel disease; monoclonal antibodies; pharmacodynamics; pharmacokinetics; population modeling

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; FC RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; INFLIXIMAB; MONOCLONAL ANTIBODY;

ARTICLE; BAYES THEOREM; CLINICAL PRACTICE; COMPUTER PROGRAM; CROHN DISEASE; DECISION SUPPORT SYSTEM; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; INTERPERSONAL COMMUNICATION; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; MEDICAL EDUCATION; MOLECULAR WEIGHT; MONOTHERAPY; MULTIPLE MYELOMA; PERSONALIZED MEDICINE; PHARMACODYNAMICS; RECEPTOR AFFINITY; T CELL LYMPHOMA; THERMODYNAMICS; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL; DECISION SUPPORT SYSTEMS, CLINICAL; HUMANS; INDIVIDUALIZED MEDICINE;

EID: 84923358995     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.370     Document Type: Article

References (72)

1. Baumgart DC, Carding SR,. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007; 369 (9573): 1627-1640.
2. Travis SP, Stange EF, Lémann M, Oresland T, Chowers Y, Forbes A, D'Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel JF, Gionchetti P, Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen NJ,. European Crohnés and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohnés disease: current management. Gut. 2006; 55 (Suppl 1): i16-i35.
3. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF,. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008; 6 (6): 644-653.
4. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR,. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010; 59 (1): 49-54.
5. Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T,. RISING study. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol. 2009; 19 (5): 478-487.
6. Imaeda H, Takahashi K, Fujimoto T, et al. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease [published online ahead of print April 11. J Gastroenterol. 2013: DOI: 10.1007/s00535-013-0803-4.
7. Billioud V, Sandborn WJ, Peyrin-Biroulet L,. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol. 2011; 106 (4): 674-684.
8. Miskulin DC, Weiner DE, Tighiouart H, et al. Medical Directors of Dialysis Clinic Inc. Computerized decision support for EPO dosing in hemodialysis patients. Am J Kidney Dis. 2009; 54 (6): 1081-1088.
9. Montazeri A, Culine S, Laguerre B, et al. Individual adaptive dosing of topotecan in ovarian cancer. Clin Cancer Res. 2002; 8 (2): 394-399.
10. Barrett JS, Mondick JT, Narayan M, Vijayakumar K, Vijayakumar S,. Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy. BMC Med Inform Decis Mak. 2008; 8: 6. DOI: 10.1186/1472-6947-8-6.
11. Holford SD, Holford NHG, Anderson BJ,. Online dose calculation tool for determining dosing regimens in the very young. PAGANZ website. http://www.paganz.org/wp-content/uploads/2013/01/Online-dose-calculation-tool-for-determining-dosing-regimens-in-the-very-young1.pdf. Accessed July 5, 2013.
12. Shaw G,. Clinical modeling hits prime time. Drug Discovery and Development website. http://www.dddmag.com/articles/2007/09/clinical-modeling-hits-prime-time. Published September 6, 2007. Accessed July, 5 2013.
13. Xu Z, Davis HM, Zhou H,. Rational development and utilization of antibody-based therapeutic proteins in pediatrics. Pharmacol Ther. 2013; 137 (2): 225-247.
14. Xu Z, Mould DR, Hu C, Ford J, Keen M, Davis HM, Zhou H,. "A Population-Based Pharmacokinetic Pooled Analysis of Infliximab in Pediatrics" ACCP National Meeting 2012 San Diego CA.
15. Wang W, Wang EQ, Balthasar JP,. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008; 84 (5): 548-558.
16. Waldmann TA, Strober W,. Metabolism of immunoglobulins. Prog Allergy. 1969; 13: 1-110.
17. Mould DR,. In:, Ette E, Williams P, eds., Using Pharmacometrics in the Development of Biological Therapeutic Biological Agents In Pharmacometrics: The Science of Quantitative Pharmacology. Chapter 41 Hoboken, NJ: John Wiley and Sons. 2007.
18. Ordás I, Mould DR, Feagan BG, Sandborn WJ,. " Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetic Based Dosing Paradigms." Clin Pharmacol Ther. 2012; 91 (4): 635-646.
19. Mould DR, Baumann A, Kuhlmann J, et al. Population Pharmacokinetics pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukemia. Br J Clin Pharmacol. 2007; 64 (3): 278-291.
20. Lowe PJ, Tannenbaum S, Gautier A, Jimenez P,. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol. 2009; 68 (1): 61-76.
21. Mould DR, Green B,. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs. 2010; 24 (1): 23-39.
22. Brambell FW, Hemmings WA, Morris IG,. A theoretical model of gamma-globulin catabolism. Nature. 1964; 203: 1352-1354.
23. Telleman P, Junghans RP,. The role of the Brambell receptor (FcRB) in liver: protection of endocytosed immunoglobulin G (IgG) from catabolism in hepatocytes rather than transport of IgG to bile. Immunology. 2000; 100 (2): 245-251.
24. Zhu X, Meng G, Dickinson BL, Li X, Mizoguchi E, Miao L, et al. MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. J Immunol. 2001; 166 (5): 3266-3276.
25. Morell A, Terry WD, Waldmann TA,. Metabolic properties of IgG subclasses in man. J. Clin Invest. 1970; 49 (4): 673-680.
26. Marks J,. Antibody formation in myelomatosis. J Clin Pathol. 1953; 6 (1): 62-63.
27. Ober RJ, Radu CG, Ghetie V, Ward ES,. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol. 2001; 13 (12): 1551-1559.
28. Ternant D,. Pharmacokinectis and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther. 2005: S37-S47.
29. Cohen-Solal JF, Cassard L, Fridman WH, Sautes-Fridman C,. Fc gamma receptors. Immunol Lett. 2004; 92 (3): 199-205.
30. Reddy MP, Kinney CA, Chaikin MA, et al. Elimination of Fc receptor dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J Immunol. 2000; 164 (4): 1925-1933.
31. Mortensen DL, Prabhu S, Stefanich EG, Kadkhodayan-Fischer S, Gelzleichter TR, Baker D, Jiang J, Wallace K, Iyer S, Fielder PJ, Putnam WS,. Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies. MAbs. 2012; 4 (6): 724-731.
32. Louis E, et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther. 2004; 19 (5): 511-519.
33. Weiner LM,. Monoclonal antibody therapy of cancer. Semin Oncol. 1999; 26: 43-51.
34. Schellekens H,. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov. 2002; 1 (6): 457-462.
35. Brinks V, Jiskoot W, Schellekens H,. Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res. 2011; 28: 2379-2385.
36. Kijanka G, Jiskoot W, Schellekens H, Brinks V,. Effect of treatment regimen on the immunogenicity of human interferon Beta in immune tolerant mice. Pharm Res. 2013; 30 (6): 1553-1560.
37. Stephens S, Emtage S, Vetterlein O, Chaplin L, Bebbington C, Nesbitt A, Sopwith M, Athwal D, Novak C, Bodmer M,. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology. 1995; 85 (4): 668-674.
38. Mould DR,. Using pharmacometrics in the development of biological therapeutic biological agents. In:, Ette E, Williams P, eds., Pharmacometrics: the science of quantitative pharmacology. Hoboken (NJ): John Wiley and Sons. 2007.
39. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans B,. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006; 54 (3): 711-715.
40. Porter CHJ, Charman SA,. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci. 2000; 89 (3): 297-310.
41. Kagan L, Gershkovich P, Mendelman A, Amsili S, Ezov N, Hoffman A,. The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. Eur J Pharm Biopharm. 2007; 67: 759-765.
42. Lobo ED, Hansen RJ, Balthasar JP,. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004; 93: 2645-2668.
43. Wang W, Chen N, Shen X, Cunningham P, Fauty S, Michel K, Wang B, Hong X, Adreani C, Nunes CN, Johnson CV, Yin KC, Groff M, Zou Y, Liu L, Hamuro L, Prueksaritanont T,. Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs. Drug Metab Dispos. 2012; 40 (5): 952-962.
44. Dubinsky MC, Mei L, Friedman M, Dhere T, Haritunians T, Hakonarson H, Kim C, Glessner J, Targan SR, McGovern DP, Taylor K, Rotter J,. Genome Wide association (GWA) predictors of anti-TNF therapeutic responsiveness in pediatric Inflammatory bowel disease. Inflamm Bowel Dis. 2010; 16: 1357-1366.
45. Arijs I, Li K, Toedter G, Quintens R, Van Lommel L, Van Steen K, Leemans P, De Hertogh G, Lemaire K, Ferrante M, Schnitzler F, Thorrez L, Ma K, Song XY, Marano C, Van Assche G, Vermeire S, Geboes K, Schuit F, Baribaud F, Rutgeerts P,. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut. 2009; 58 (12): 1612-1619.
46. Rutgeerts P, Van Assche G, Vermeire S,. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology. 2004; 126 (6): 1593-1610.
47. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348: 601-608.
48. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P,. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology. 2003; 124 (4): 917-924.
49. Maser EA, Villela R, Silverberg MS, Greenberg GR,. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4 (10): 1248-1254.
50. Roblin X, Marotte H, Rinaudo M, Del Tedesco E, Moreau A, Phelip JM, Genin C, Peyrin-Biroulet L, Paul S,. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014; 12 (1): 80-84.
51. Colombel JF, Sandborn WJ, Allez M, Dupas JL, Dewit O, D'Haens G, Bouhnik Y, Parker G, Pierre-Louis B, Hébuterne X,. Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2013: 01679-01670. DOI: 10.1016/j.cgh.2013.10.025. [Epub ahead of print].
52. Colombel JF1, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P,. SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362 (15): 1383-1395.
53. Ben-Horin S, Waterman M, Kopylov U, Yavzori M, Picard O, Fudim E, Awadie H, Weiss B, Chowers Y,. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013; 11 (4): 444-447.
54. Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED,. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013; 108 (1): 99-105.
55. Bortlik M1, Duricova D, Malickova K, Machkova N, Bouzkova E, Hrdlicka L, Komarek A, Lukas M,. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis. 2013; 7 (9): 736-743.
56. Lesko LJ, Schmidt S,. Individualization of drug therapy: history, present state, and opportunities for the future. Clin Pharmacol Ther. 2012; 92 (4): 458-466.
57. Sivyer A,. A dose-rate calculator. Br J Radiol. 1959; 32 (375): 208-209.
58. Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL,. International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014; 14 (6): 498-509.
59. Sheiner LB, Beal S, Rosenberg B, Marathe VV,. Forecasting individual pharmacokinetics. Clin Pharmacol Ther. 1979; 26 (3): 294-305.
60. Canaday BR, Sawyer WT,. A pocket calculator program for prediction of warfarin maintenance dose. Comput Biol Med. 1982; 12 (2): 179-187.
61. Jelliffe RW, Maire P, Sattler F, Gomis P, Tahani B,. Adaptive control of drug dosage regimens: basic foundations, relevant issues, and clinical examples. Int J Biomed Comput. 1994; 36 (1-2): 1-23.
62. Conti R, Veenstra DL, Armstrong K, Lesko LJ, Grosse SD,. Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Making. 2010; 30 (3): 328-340.
63. Kravitz RL, Neufeld JD, Hogarth MA, Paterniti DA, Dager W, White RH,. From insight to implementation: lessons from a multi-site trial of a PDA-based warfarin dose calculator. In:, Henriksen K, Battles JB, Marks ES, Lewin DI, eds., Advances in Patient Safety: From Research to Implementation (Volume 3: Implementation Issues). Rockville (MD): Agency for Healthcare Research and Quality (US). 2005.
64. Tobler A, Mühlebach S,. Intravenous phenytoin: a retrospective analysis of Bayesian forecasting versus conventional dosing in patients. Int J Clin Pharm. 2013; 35 (5): 790-797.
65. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH,. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 1998; 338 (8): 499-505.
66. van Lent-Evers NA, Mathôt RA, Geus WP, van Hout BA, Vinks AA,. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit. 1999; 21 (1): 63-73.
67. IEEE Recommended Practice for Software Requirements Specifications. Approved 25 June 1998. IEEE-SA Standards Board.
68. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial [published online ahead of print July 22,. Gut. 2013:DOI: 10.1136/gutjnl-2013-305279.
69. Xu Z, Mould DR, Hu C, Ford J, Keen M, Davis HM, Zhou H,. "A Population-Based Pharmacokinetic Pooled Analysis of Infliximab in Pediatrics" ACCP National Meeting 2012 San Diego CA.
70. Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM,. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011; 33 (7): 946-946.
71. Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, Davis HM, Zhou H,. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009; 65 (12): 1211-1228.
72. Mould DR, Moyer B, Amur S, Mukherjee A,. " The Impact of New Technologies on the Science of Clinical Care and Drug Development ". AAPS Magazine December. 2013.